Sign In
Buy NVO
$47.41
-0.0100 (-0.0211%)
At Close: Jun 24, 2026
NEW YORK, Sept. 17, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Novo Nordisk A/S (NYSE: NVO) between May 7, 2025 and July 28,
Novo Nordisk A/S (NVO) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
04:14pm, Wednesday, 17'th Sep 2025
BENSALEM, Pa , Sept. 17, 2025 /PRNewswire/ -- The Law Offices of Howard G.
Novo Nordisk Stock Is a Better Obesity Play Than Eli Lilly, Berenberg Says
11:26am, Wednesday, 17'th Sep 2025
Novo Nordisk is “no longer the elephant in the room,” Berenberg analysts say.
Why Novo Nordisk Stock Popped Today
11:02am, Wednesday, 17'th Sep 2025
Novo Nordisk (NVO 2.83%) -- the original Ozempic stock -- got a boost from private German bank Berenberg this morning, which upgraded the stock to buy. In fact, Berenberg says Novo is its "preferred o
NVO Stock Rises on Upbeat Phase III Data for Cagrilintide in Obesity
10:56am, Wednesday, 17'th Sep 2025
Novo Nordisk stock rises as its next-generation subcutaneous obesity treatment candidate, cagrilintide, delivers meaningful weight loss in a phase III obesity study.
GLP-1 drugs could save millions of lives — and spark a pension crisis
10:05am, Wednesday, 17'th Sep 2025
GLP-1 drugs are so powerful that, in 20 years, they can save millions from premature death, a leading insurance company says.
Novo Nordisk finds its footing again
09:48am, Wednesday, 17'th Sep 2025
After a bruising year, Novo Nordisk (NYSE:NVO) is back in favour. Berenberg has upgraded the Danish drugmaker to 'buy', setting a target price of DKK425 against a current DKK359.
Eli Lilly's obesity pill outperforms Novo Nordisk's oral drug in head-to-head diabetes trial
09:00am, Wednesday, 17'th Sep 2025
Eli Lilly said its experimental pill outperformed Novo Nordisk's own oral drug in the first head-to-head study comparing the two medicines in patients with Type 2 diabetes. Eli Lilly said its pill,
PHILADELPHIA , Sept. 17, 2025 /PRNewswire/ -- Berger Montague PC is investigating claims under the federal securities laws against Novo Nordisk A/S (NYSE: NVO) ("Novo" or the "Company"), a globa
Novo Nordisk's Alzheimer's trial a 'lottery ticket', senior executive says
06:33am, Wednesday, 17'th Sep 2025
A senior Novo Nordisk executive on Wednesday described the drugmaker's ongoing trial of its blockbuster obesity medicine for treatment of Alzheimer's disease as a "lottery ticket" due to its uncertain
2 High-Yield Dividend Stocks You'll Wish You Had Bought 10 Years From Now
05:16am, Wednesday, 17'th Sep 2025
Are you more interested in overall gains or generating a large stream of passive income? If you're not sure, I've got great news.
Final Trade: ORCL, NVO, VLO, VEA
06:22pm, Tuesday, 16'th Sep 2025
The final trades of the day with CNBC's Melissa Lee and the Fast Money traders.
Why Novo Nordisk Stock Popped Today
05:33pm, Tuesday, 16'th Sep 2025
On Tuesday, there were two key news items from Novo Nordisk (NVO 2.83%) for investors to digest. The pharmaceutical company, best known for its highly popular Wegovy obesity medication, unveiled resul
Class Action Filed Against Novo Nordisk A/S (NVO) Seeking Recovery for Investors – Contact Levi & Korsinsky
05:14pm, Tuesday, 16'th Sep 2025
NEW YORK, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Novo Nordisk A/S ("Novo" or the "Company") (NYSE: NVO) of a class action securities lawsuit.
Investors can contact the law firm at no cost to learn more about recovering their losses
